Lung Cancer最新文献

{"title":"Validation of the 9th edition of the TNM staging system for limited-stage small cell lung cancer after Resection: A multicenter study","authors":"Leilei Wu ,&nbsp;Jia-Yuan Tian ,&nbsp;Ming-Jun Li ,&nbsp;Feng Jiang ,&nbsp;Li-Hong Qiu ,&nbsp;Wan-Jun Yu ,&nbsp;Xiao-Lu Chen ,&nbsp;Rang-Rang Wang ,&nbsp;Kun Li ,&nbsp;Guo-Wei Ma ,&nbsp;Jian Zeng ,&nbsp;Dong Xie","doi":"10.1016/j.lungcan.2025.108085","DOIUrl":"10.1016/j.lungcan.2025.108085","url":null,"abstract":"<div><h3>Objectives</h3><div>The 9th edition of the tumor-node-metastasis (TNM) staging system for lung cancer was proposed at the 2023 World Conference on Lung Cancer in Singapore. This study aimed to externally validate and compare the latest staging of small-cell lung cancer (SCLC).</div></div><div><h3>Methods</h3><div>Four hundred and eight patients with limited-stage SCLC were collected after lung resection from four centers. Survival curves by TNM stages were drawn using the Kaplan-Meier method and further compared by the Log-rank test. The Cox regression, receiver operating characteristics curves, area under the curve (AUC), Akaike information criterion (AIC), Bayesian information criterion (BIC), and Concordance index (C-index) were used in this study.</div></div><div><h3>Results</h3><div>In comparing IA <em>vs.</em> IIB, IIA <em>vs.</em> IIB, IIA <em>vs.</em> IIIA, IIA <em>vs.</em> IIIB, and IIIA <em>vs.</em> IIIB, the 9th edition had a better distinguishing ability than the eighth staging system (all <em>p</em> &lt; 0.05). Besides, the 9th edition TNM staging had better predictive power and accuracy for the overall survival (OS) of SCLC patients over the 8th edition (AUC of 3-year OS: 0.680 <em>vs.</em> o.668; AIC: 4425.25 <em>vs.</em> 4444.52; BIC: 4493.44 <em>vs.</em> 4512.71; C-index: 0.637 [0.04] <em>vs.</em> 0.629 [0.039], <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Our external validation demonstrates that the ninth edition of pathological TNM staging for limited-stage SCLC is reasonable and valid based on a multicenter study. The ninth edition has better prognostic accuracy than the eighth edition.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108085"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer","authors":"Stephanie P.L. Saw ,&nbsp;Wen-Zhao Zhong ,&nbsp;Rui Fu ,&nbsp;Molly S.C. Li ,&nbsp;Yasushi Goto ,&nbsp;Stephen B. Fox ,&nbsp;Yasushi Yatabe ,&nbsp;Boon-Hean Ong ,&nbsp;Calvin S.H. Ng ,&nbsp;David D.W. Lee ,&nbsp;Pham Cam Phuong ,&nbsp;In Kyu Park ,&nbsp;James C.H. Yang ,&nbsp;Masahiro Tsuboi ,&nbsp;Lye Mun Tho ,&nbsp;Thomas John ,&nbsp;Hsao-Hsun Hsu ,&nbsp;Daniel S.W. Tan ,&nbsp;Tony S.K. Mok ,&nbsp;Thanyanan Reungwetwattana ,&nbsp;Navneet Singh","doi":"10.1016/j.lungcan.2024.108076","DOIUrl":"10.1016/j.lungcan.2024.108076","url":null,"abstract":"<div><div>The <em>peri</em>-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy. However, many unanswered questions and challenges remain, including the application of clinical trial data to routine clinical practice. Recognising the unique demographic profile of Asian patients with NSCLC and heterogeneous healthcare systems, the Asian Thoracic Oncology Research Group (ATORG) convened a consensus meeting in Singapore on 26 April 2024 to discuss relevant issues spanning diagnostic testing to post-neoadjuvant treatment considerations and future directions. An interdisciplinary group of 19 experts comprising medical oncologists, thoracic surgeons, radiation oncologists, pulmonologists and pathologists from Singapore, Hong Kong, Mainland China, Korea, Japan, Taiwan, India, Malaysia, Thailand, Vietnam and Australia met to discuss emerging data, identify existing gaps in clinical care and develop a multidisciplinary, multinational expert consensus statement on the <em>peri</em>-operative management of NSCLC tailored to the Asia-Pacific region.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108076"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group","authors":"L. Decoster ,&nbsp;D.R. Camidge ,&nbsp;J.A. Fletcher ,&nbsp;A. Addeo ,&nbsp;A. Greystoke ,&nbsp;K. Kantilal ,&nbsp;L.Bigay Game ,&nbsp;R. Kanesvaran ,&nbsp;F. Gomes","doi":"10.1016/j.lungcan.2025.108087","DOIUrl":"10.1016/j.lungcan.2025.108087","url":null,"abstract":"<div><div>Lung cancer is mostly a disease of aging with approximately half of newly diagnosed patients being 70 years or older. Treatment decisions in this population pose unique challenges because of their heterogeneity with regards to daily functioning, cognition, organ function, comorbidities and polypharmacy, their underrepresentation in clinical trials and the impact of treatment on patient-centered outcomes, particularly in frail patients.</div><div>The advent of targeted therapies and immunotherapy has revolutionized the management of advanced non-small cell lung cancer (NSCLC). Molecular profiling has allowed for the identification of actionable genomic alterations and targeted therapies have become standard of care for oncogene-driven NSCLC, significantly improving prognosis and quality of life. However, the data on the efficacy and tolerability of these treatments in older patients remain sparse.</div><div>This review, conducted by the International Society of Geriatric Oncology (SIOG) NSCLC task force, examines the available literature on the use of targeted therapies in patients aged 70 years or older with oncogene-driven NSCLC. The task force’s expert recommendations aim to guide treatment decisions for older patients with oncogene driven NSCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108087"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile","authors":"Daisuke Narita ,&nbsp;Eiji Hishinuma ,&nbsp;Risa Ebina-Shibuya ,&nbsp;Eisaku Miyauchi ,&nbsp;Naomi Matsukawa ,&nbsp;Ikuko N. Motoike ,&nbsp;Kengo Kinoshita ,&nbsp;Seizo Koshiba ,&nbsp;Yoko Tsukita ,&nbsp;Hirotsugu Notsuda ,&nbsp;Nozomu Kimura ,&nbsp;Ryota Saito ,&nbsp;Koji Murakami ,&nbsp;Naoya Fujino ,&nbsp;Tomohiro Ichikawa ,&nbsp;Mitsuhiro Yamada ,&nbsp;Tsutomu Tamada ,&nbsp;Hisatoshi Sugiura","doi":"10.1016/j.lungcan.2025.108082","DOIUrl":"10.1016/j.lungcan.2025.108082","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer is the deadliest disease globally, with more than 120,000 diagnosed cases and more than 75,000 deaths annually in Japan. Several treatment options for advanced lung cancer are available, and the discovery of biomarkers will be useful for personalized medicine. Using metabolome analysis, we aimed to identify biomarkers for diagnosis and treatment response by examining the changes in metabolites associated with lung cancer progression.</div></div><div><h3>Methods</h3><div>Plasma samples from patients with recurrent or metastatic non-small cell lung carcinomas diagnosed at Tohoku University Hospital between 2019 and 2024 were used in this study. Metabolomic analysis was performed using the Biocrates Life Sciences MxP Quant 500 kit. Multivariate, principal component, and orthogonal partial least squares discriminant analyses were performed.</div></div><div><h3>Results</h3><div>The triglyceride and phosphatidylcholine concentrations were higher in the patients with early than in those with advanced lung adenocarcinomas. However, the cholesterol ester concentrations were higher for the patients with advanced lung cancer. The concentrations of hexosylceramide were higher in patients with early lung adenocarcinoma than in those with squamous cell carcinoma. Relative to <em>epidermal growth factor receptor</em> (<em>EGFR</em>)-mutation negative cases, the <em>EGFR</em>-mutation positive cases showed marked differences between the ceramide and triglyceride concentrations. For the best therapeutic effect of EGFR-TKI treatment, the hexosylceramide (HexCer) (d18:1/24:0), ceramide (Cer) (d18:2/22:0), and ceramide (Cer) (d18:2/24:0) concentrations were higher for the stable and progressive disease groups. The concentrations of phosphatidylcholine (PC) ae C42:2, sphingomyelin (SM) C24:1, and lysophosphatidylcholine (lysoPC) a C18:2 were higher in the partial response group treated with immune checkpoint inhibitors and chemotherapy.</div></div><div><h3>Conclusion</h3><div>Metabolomic analysis may be useful for the diagnosis and treatment of lung cancer and may provide clues for new therapeutic strategies. PC ae C42:2, SM C24:1, and lysoPC a C18:2 can serve as predictive biomarkers for monitoring the therapeutic effects of the combination of immune checkpoint inhibitors and chemotherapy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108082"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients","authors":"Tae Hata ,&nbsp;Tadaaki Yamada ,&nbsp;Yasuhiro Goto ,&nbsp;Akihiko Amano ,&nbsp;Yoshiki Negi ,&nbsp;Satoshi Watanabe ,&nbsp;Naoki Furuya ,&nbsp;Tomohiro Oba ,&nbsp;Tatsuki Ikoma ,&nbsp;Akira Nakao ,&nbsp;Keiko Tanimura ,&nbsp;Hirokazu Taniguchi ,&nbsp;Akihiro Yoshimura ,&nbsp;Tomoya Fukui ,&nbsp;Daiki Murata ,&nbsp;Kyoichi Kaira ,&nbsp;Shinsuke Shiotsu ,&nbsp;Makoto Hibino ,&nbsp;Asuka Okada ,&nbsp;Yusuke Chihara ,&nbsp;Koichi Takayama","doi":"10.1016/j.lungcan.2025.108104","DOIUrl":"10.1016/j.lungcan.2025.108104","url":null,"abstract":"<div><h3>Background</h3><div>Clinical trial eligible patients with advanced non-small cell lung cancer (aNSCLC) and low programmed cell death ligand 1 (PD-L1) expression achieve greater benefit from immune checkpoint inhibitor (ICI) combination chemotherapy (ICI-Chemo) compared with Chemo alone. We examined whether patients ineligible for clinical trials may benefit from ICI-Chemo.</div></div><div><h3>Methods</h3><div>This multicenter retrospective cohort study enrolled patients with aNSCLC, including unresectable Stage III (IIIB/IIIC) and IV disease with a PD-L1 tumor proportion score of 1–49% treated with ICI-Chemo or Chemo as first-line therapy from 2018 to 2023 in Japan. Treatment outcome and safety of ICI-Chemo versus Chemo groups in trial-eligible and trial-ineligible patients was compared based on criteria from previous phase III clinical trials.</div></div><div><h3>Results</h3><div>Overall, 728 patients were analyzed: 333 trial-eligible and 395 ineligible patients. The median overall survival was 25.1 months in the ICI-Chemo group and 18.5 months in the Chemo group for eligible patients (HR 0.73, 95 %CI: 0.54–0.97) and was 18.2 months in the ICI-Chemo group and 14.9 months in the Chemo group for ineligible patients (HR 0.75, 95 %CI: 0.59–0.95). Median progression-free survival was longer with ICI-Chemo in both groups. For ineligible patients, performance status (PS) ≥ 2 and squamous cell carcinoma (SqCC) were clinical factors associated with worse survival prognosis, and survival outcomes with ICI-Chemo and Chemo were comparable. The ineligible group had no increase in severe adverse events compared to the eligible group.</div></div><div><h3>Conclusions</h3><div>This study suggests a possible clinical benefit of receiving ICI-Chemo for trial-ineligible patients with low PD-L1 expression, excluding those with PS ≥ 2 or SqCC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108104"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"90 Real world data analysis of neoadjuvant Nivolumab in combination with platinum-based chemotherapy in operable non–small cell lung cancer (NSCLC). The Guy's cancer centre experience","authors":"Toki Maria ,&nbsp;Elkhalifa Mohammed ,&nbsp;Bille Andrea ,&nbsp;Tan Carol ,&nbsp;Ashrafian Leanne ,&nbsp;Okiror Lawrence ,&nbsp;Fraser Stephanie ,&nbsp;Mclean Emma ,&nbsp;Smith Daniel ,&nbsp;Ahmed Shahreen ,&nbsp;Skwarski Michael ,&nbsp;Santis George ,&nbsp;Ryanna Kimuli ,&nbsp;Morton Cienne ,&nbsp;Ghosh Sharmistha ,&nbsp;Karapanagiotou Eleni ,&nbsp;Gennatas Spyridon ,&nbsp;Spicer James ,&nbsp;Georgiou Alexandros","doi":"10.1016/j.lungcan.2025.108200","DOIUrl":"10.1016/j.lungcan.2025.108200","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108200"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer","authors":"Chauhan Hiten ,&nbsp;Yeo Daniel ,&nbsp;Dulloo Sean ,&nbsp;Ahmed Samreen ,&nbsp;Chauhan Meera ,&nbsp;Adhikaree Jason ,&nbsp;Khan Sam","doi":"10.1016/j.lungcan.2025.108196","DOIUrl":"10.1016/j.lungcan.2025.108196","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108196"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/j.lungcan.2025.108392","DOIUrl":"10.1016/j.lungcan.2025.108392","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108392"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright Page","authors":"","doi":"10.1016/j.lungcan.2025.108393","DOIUrl":"10.1016/j.lungcan.2025.108393","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108393"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"45 Optimisation of an EBUS service at a district general hospital","authors":"Tsui Thomas ,&nbsp;Saliu Emma ,&nbsp;Graves Jenny ,&nbsp;Armstrong Adam ,&nbsp;Nadaf Nicholas","doi":"10.1016/j.lungcan.2025.108155","DOIUrl":"10.1016/j.lungcan.2025.108155","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108155"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}